Improving Survival in Early Stage NSCLC by Incorporating a 14 Gene Molecular Risk Diagnostic Assay
CTSNet hosted a live event on November 18 that aimed to shed light on
important recent developments in lung cancer treatment. The recording
is now available.
Moderated by David Jablons, MD,
University of California San Francisco, who was joined by an esteemed
panel, this live event presented data about the development of a
molecular assay based on resected tumor RNA expression from simple
paraffin-fixed tissue samples. This is integrated into an algorithm that
can assign a risk score for recurrence. This molecular risk score is
fully independent of standard TNM staging and does not rely on any other
clinical parameters. The assay has been widely validated in thousands
of patients and demonstrates both significant prognostic information and
the predictive benefit of adjuvant platinum based chemotherapy in high
risk patients, as identified by this assay.